toripalimab

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

toripalimab
May 13, 2025, 16:57 | Insight
Amol Akhade: New ADC plus IO Combo Challenges Frontline HER2+ Metastatic Urothelial Carcinoma Standard
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared a post on LinkedIn:…
May 13, 2025, 08:20 | Insight
Amol Akhade: BREAKING from China - HER2+ Bladder Cancer may have a new contender
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, posted on X: "BREAKING from China…
Apr 20, 2025, 11:06 | Drugs
Loqtorzi (Toripalimab): What patients need to know?
Toripalimab (Loqtorzi) is a PD-1 inhibitor, a type of immune checkpoint inhibitor that works by…
Apr 19, 2025, 13:12 | Drugs
Toripalimab (Loqtorzi): Uses in Cancer, Side Effects, Dosage, Expectations, and More
Toripalimab is a PD-1 inhibitor, a type of immune checkpoint inhibitor that works by blocking…
Nov 29, 2024, 18:49 | Insight
Dr. Reddy’s has launched Toripalimab in India: Advancing Treatment for Nasopharyngeal Carcinoma
Reddy’s Laboratories Ltd. has announced the launch of Toripalimab, the first and only immuno-oncology drug…
Aug 31, 2024, 12:58 | Insight
Eric Singhi: Our editorial in ASCO Daily News on the CHOICE-01 study
Eric Singhi shared a post on LinkedIn: "It’s always a pleasure to collaborate with my…
Jun 5, 2024, 12:44 | Blog
Tom Powles: Perhaps the most important long-term bladder cancer data at ASCO24
Tom Powles, Director of Barts Cancer Center, shared on X/Twitter: ''Perhaps the most important long-term…
All: 7 Posts: 1 - 100
Special Coverage